Sort
16,300 grants matching “fatty liver disease”
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,684,642Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES
Organized Lipid Matrix: Fatty Acids and Choline in Cystic Fibrosis
$2,682,829Walter A Shaw · Avanti Polar Lipids, Inc. · R44 · FY2007 · DK
Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases
$2,682,681Raphaela Goldbach-Mansky · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Advanced Fibrosis Detection and a Predictive Diagnostic Model for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care
$2,682,628Andrew David Schreiner · Medical University Of South Carolina · R01 · FY2025 · DK
Sirtuins and nuclear receptors in aging and age-associated diseases
$2,675,793Xiaoling Li · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Deciphering the Mechanisms by which Long Chain Fatty Acid Oxidation Influences Spatial Microvesicular Steatosis
$2,651,504Robert Nathaniel Helsley · University Of Kentucky · R01 · FY2025 · DK
Investigating novel mitochondrial mechanisms of obesity pathogenesis
$2,638,760Jessica Brooke Spinelli · Univ Of Massachusetts Med Sch Worcester · R01 · FY2025 · DK
Subcutaneous Drug Development for Portal Hypertension Ascites
$2,638,464Gerardo M. Castillo · Pharmain Corporation · R44 · FY2025 · DK
Obesity, Body Fat Distribution, and Cancer Risk in the Multiethnic Cohort
$2,635,247Loic Le Marchand · University Of Hawaii At Manoa · P01 · FY2016 · CA
DETECTION AND MODELS OF TOXICANT EXPOSURE
$2,634,787Robert H Tukey · University Of California, San Diego · P42 · FY2021 · ES
Triglycerides, Diabetes and Cardiovascular Disease
$2,622,487Karin E. Bornfeldt · University Of Washington · P01 · FY2025 · HL
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,620,861Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2019 · ES
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)
$2,615,402Steven A Weinman · University Of Kansas Medical Center · P20 · FY2022 · GM
Xenobiotic receptors
$2,609,568Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Hepatobiology and Toxicology COBRE
$2,608,500Craig J McClain · University Of Louisville · P20 · FY2016 · GM
Gastric Endocrine Functions in Skeletal Homeostasis
$2,608,068Ziru Li · Mainehealth · R01 · FY2025 · DK
Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases
$2,606,186Raphaela Goldbach-Mansky · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,598,686Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2020 · ES
Aging as a Risk Factor and Target for Prevention of Liver Cancer
$2,595,836Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
UTRGV Diversity Center for Genome Research
$2,591,438Sarah A. Williams-Blangero · University Of Texas Rio Grande Valley · U54 · FY2023 · HG
Aging as a Risk Factor and Target for Prevention of Liver Cancer
$2,585,444Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Aging as a Risk Factor and Target for Prevention of Liver Cancer
$2,585,419Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2023 · AG
Southern Liver Health Cohort
$2,579,511Cathrine Hoyo · North Carolina State University Raleigh · UH3 · FY2024 · CA
Advanced Non Invasive Vascular Imaging Methods
$2,577,432Ahmed Gharib · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
$2,567,925Edward A Fisher · New York University School Of Medicine · P01 · FY2023 · HL